Dna damage repair inhibitors for treatment of cancer
AssigneesThe Institute of Cancer Research: Royal Cancer Hospital, Kudos Pharmaceuticals Limited
InventorsAlan Ashworth, Stephen Jackson, Niall Martin, Graeme Cameron Murray Smith
Life of this patent
Estimating the term…
Abstract
The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Claims22
-19. (canceled)
A method of treatment of a cancer deficient in the homologous recombination (HR) dependent deoxyribonucleic acid (DNA) double strand break (DSB) repair pathway in an individual in need thereof comprising;
- administering a poly (ADP-ribose) polymerase (PARP) inhibitor to said individual.
A method of treatment of cancer in an individual in need thereof comprising;
- identifying a cell obtained from the individual as having one or more mutations or polymorphisms in a nucleic acid sequence encoding a component of the HR dependent DNA DSB repair pathway;
- and
- administering a poly (ADP-ribose) polymerase (PARP) inhibitor to said individual.
A method of treatment of cancer in an individual in need thereof comprising;
- administering a poly (ADP-ribose) polymerase (PARP) inhibitor to said individual,
- wherein a cell obtained from the individual has been previously identified as having one or more mutations or polymorphisms in a nucleic acid sequence encoding a component of the HR dependent DNA DSB repair pathway.
Dependencies are inferred from the claim text.